{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05495815",
            "orgStudyIdInfo": {
                "id": "Maryland"
            },
            "organization": {
                "fullName": "University of Maryland, Baltimore",
                "class": "OTHER"
            },
            "briefTitle": "Proper Duration of Suppressive Antibiotic Therapy After Debridement, Antibiotics, and Implant Retention",
            "officialTitle": "Randomized Clinical Trial Determining Proper Duration of Suppressive Antibiotic Therapy After Total Joint Arthroplasty Debridement, Antibiotics, and Implant Retention",
            "acronym": "ProperSAT",
            "therapeuticArea": [
                "Infectious Diseases",
                "Other"
            ],
            "study": "proper-duration-of-suppressive-antibiotic-therapy-after-debridement-antibiotics-and-implant-retention"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-04",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-06",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-08-05",
            "studyFirstSubmitQcDate": "2022-08-08",
            "studyFirstPostDateStruct": {
                "date": "2022-08-10",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-04-07",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-09",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Sumon Nandi",
                "investigatorTitle": "Associate Professor, Chief of Adult Reconstruction",
                "investigatorAffiliation": "University of Maryland, Baltimore"
            },
            "leadSponsor": {
                "name": "University of Maryland, Baltimore",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "OrthoCarolina Research Institute, Inc.",
                    "class": "OTHER"
                },
                {
                    "name": "University of Pennsylvania",
                    "class": "OTHER"
                },
                {
                    "name": "University of Arkansas",
                    "class": "OTHER"
                },
                {
                    "name": "OrthoMichigan",
                    "class": "UNKNOWN"
                },
                {
                    "name": "NYU School of Medicine",
                    "class": "UNKNOWN"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "Multiple studies have demonstrated oral suppressive antibiotic therapy (SAT), after intravenous antibiotics, maximizes reoperation-free survival of total joint arthroplasty (TJA) debridement, antibiotics, and implant retention (DAIR) for acute periprosthetic joint infection (PJI). However, little is known regarding sequelae of SAT after DAIR for PJI. Prior studies have small or heterogeneous patient cohorts, variable antibiotic regimens, arrive at disparate conclusions, and do not establish antibiotic resistance risk.\n\nThe investigators propose a prospective randomized controlled multicenter study to expand on findings in a retrospective, multi-center pilot study. Study aims are to evaluate SAT after DAIR of acutely infected primary TJA regarding: 1) adverse drug reactions/intolerance; 2) reoperation for infection; and 3) antibiotic resistance."
        },
        "conditionsModule": {
            "conditions": [
                "Periprosthetic Joint Infection",
                "Antibiotic Suppression"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "NA"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 438,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "6 months of SAT",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "TJA DAIR, followed by 6 weeks of IV antibiotics then 6 months of oral suppressive antibiotic therapy",
                    "interventionNames": [
                        "Drug: 6 months of SAT"
                    ]
                },
                {
                    "label": "12 months of SAT",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "TJA DAIR, followed by 6 weeks of IV antibiotics then 12 months of oral suppressive antibiotic therapy",
                    "interventionNames": [
                        "Drug: 12 months of SAT"
                    ]
                },
                {
                    "label": "Indefinite SAT",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "TJA DAIR, followed by 6 weeks of IV antibiotics then indefinite oral suppressive antibiotic therapy",
                    "interventionNames": [
                        "Drug: Indefinite SAT"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "6 months of SAT",
                    "description": "6 months of oral suppressive antibiotic therapy",
                    "armGroupLabels": [
                        "6 months of SAT"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "12 months of SAT",
                    "description": "12 months of oral suppressive antibiotic therapy",
                    "armGroupLabels": [
                        "12 months of SAT"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Indefinite SAT",
                    "description": "Indefinite oral suppressive antibiotic therapy",
                    "armGroupLabels": [
                        "Indefinite SAT"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Reoperation for infection recurrence",
                    "timeFrame": "2 years after patient enrollment"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Antibiotic resistance, evidenced by change in antimicrobial sensitivity profile, developed by infecting organism after suppressive antibiotic therapy causing infection recurrence",
                    "timeFrame": "At time of reoperation (within 2 years of patient enrollment)"
                },
                {
                    "measure": "Adverse drug reaction or intolerance, defined as any symptom or laboratory value derangement requiring a change in, or discontinuation of, antimicrobial therapy",
                    "description": "Antibiotic intolerance is any Grade I sign from CTCAE v5.0, while adverse drug reaction is any Grade 2 sign or higher.",
                    "timeFrame": "During antibiotic administration (up to 2 years after patient enrollment)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* over 18 years-old\n* underwent DAIR with modular component exchange for acute TJA PJI, as defined by Musculoskeletal Infection Society Criteria, with symptom duration less than 4 weeks\n* on postoperative oral SAT for at least 3 months\n\nExclusion Criteria:\n\n* underwent aseptic revision surgery\n* had one-stage, 1.5-stage, or two-stage revision surgery\n* did not have postoperative SAT\n* did not have follow-up that allowed for evaluation of SAT sequelae",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "locations": [
                {
                    "facility": "University of Maryland",
                    "status": "RECRUITING",
                    "city": "Baltimore",
                    "state": "Maryland",
                    "zip": "21201",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Sumon Nandi",
                            "role": "CONTACT",
                            "phone": "617-717-8065",
                            "email": "sumon.nandi@som.umaryland.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.29038,
                        "lon": -76.61219
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M10283",
                    "name": "Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M6368",
                    "name": "Communicable Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC01",
                    "name": "Infections"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M4222",
                    "name": "Anti-Bacterial Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4224",
                    "name": "Antibiotics, Antitubercular",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}